We examined whether administration of menatetrenone (vitamin K 2 ) improves bone metabolism in continuous ambulatory peritoneal dialysis (CAPD) patients. Administration of a single dose of menatetrenone (15 mg) revealed that the 24-h pharmacodynamics in CAPD patients were comparable to those in control individuals. In a 12-month period of oral menatetrenone administration (45 mg/day), eight stable CAPD patients were studied for blood-bone metabolism parameters and for bone mineral content.
Introduction
With the increasing use of dialysis and other associated factors, such as an increased population of long-term dialysis patients and a tendency for the starting age for dialysis to be higher, the average age of dialysis patients in Japan is more than 60 years. 1 In patients with chronic renal insufficiency, particularly the elderly, changes in blood chemistry can lead to an increased risk of osteoporosis, as well as osteitis fibrosa. These conditions are important determinants for activities of daily living and quality of life in such patients. Bone mineral density decreases with ageing to a greater extent in dialysis patients than in the general population, with no appreciable difference between patients on haemodialysis and those on continuous ambulatory peritoneal dialysis (CAPD). 2 In addition to the reduction in bone mineral content, secondary hyper-parathyroidism, a recognized complication of dialysis, further reduces bone density. In CAPD patients, persistent hypercalcaemia is likely to develop because the calcium balance through the peritoneum is positive when the calcium concentration in the dialysate is high. Routine administration of calcium-based phosphate binders may increase calcium absorption through the intestine. Administration of active vitamin D 3 (1,25(OH) 2 D 3 ) preparations, a common practice in haemodialysis patients, is also associated with an increase in serum calcium levels, so this strategy may not be suitable for CAPD patients. It is said that blood vitamin K deficiency is associated with bone fracture in haemodialysis patients. 3 Menatetrenone (vitamin K 2 ) is reported to increase bone mass in patients with osteoporosis. 4 Another study has found that menatetrenone concentration in the blood of dialysis patients is lower than in previously reported healthy adults. 5 As dialytic osteopathy exhibits a tendency similar to that of primary osteoporosis, administration of menatetrenone is expected to improve bone metabolism, independently of 1,25(OH) 2 D 3 and parathyroid hormone, in this condition also.
In the present study, which was carried out in two parts, we first examined the pharmacodynamics of single-dose menatetrenone (oral preparation Glakay ® , Eisai Co. Ltd, Tokyo, Japan) in CAPD patients. Secondly, the effects of 12 months' administration of oral menatetrenone on bone metabolism parameters were investigated.
Patients and methods

PHARMACODYNAMICS IN SINGLE-DOSE ADMINISTRATION
Four CAPD patients attending our out-patient clinic ( Table 1) were studied. All had chronic glomerulonephritis, had been undergoing CAPD for at least 3 years, were stable and had no major visceral complications. Patients with hepatobiliary complications that impair fat absorption or receiving warfarin treatment were not included. Before the study began, informed written consent was obtained from all patients.
On the first day of the study, CAPD bags were exchanged at 07.00. At 08.00, each patient had a meal containing 38.4 g of fat.
The fat content of each meal had to be consistent as an increased fat intake increases the absorption of vitamin K.
Oral menatetrenone 15 mg was administered after 30 min, following urination. Blood was drawn 90 min before and 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, 12 h and 21.5 h after menatetrenone administration. Dialysis bags were exchanged at 3 h, 9 h, 13.5 h and 21.5 h after menatetrenone administration, and urine was pooled for 24 h.
Heparinized blood, 3.0 ml per sample, was collected and immediately centrifuged at 4°C and 3000 rpm (H-500R, Kokusan, Tokyo) for 10 min, after which plasma was separated. The plasma sample was immediately transferred to a shaded vinyl tube and stored frozen at less than -20°C until analysis. For dialysate and urine, 15 ml was transferred from each dialysate bag or shaded pooled urine container to a storage container, which was immediately placed in a shaded vinyl bag and stored frozen at -20°C or below until analysis.
Determination of vitamin K
After drug administration, blood samples were analysed, over time, using high performance liquid chromatography for menatetrenone concentrations. In addition, CAPD effluents and urine samples were assayed for menatetrenone and its metabolites: menatetrenone, menatetrenone-glucuronic acid conjugate, K-acid I and K-acid I glucuronic acid conjugate and K-acid II and K-acid II glucuronic acid conjugate ( Fig. 1 ). Detection limits for the respective tests were 0.1 ng/ml for menatetrenone and its conjugate, 10.5 ng/ml for K-acid I and its conjugate, and 10.9 ng/ml for K-acid II and its conjugate.
LONG-TERM ADMINISTRATION STUDY
Eight CAPD patients being managed at our hospital ( Table 2) were studied. Oral menatetrenone 45 mg/day (three daily doses of 15 mg) was administered for 12 months. All patients had chronic glomerulonephritis, had been undergoing CAPD for at least 3 months and had intact parathyroid hormone (i-PTH) levels of 500 pg/ml or lower.
Patients with serious complications, such as diabetes mellitus, hepatic or heart failure; with oil-soluble drug absorption insufficiency, such as in cholecystitis or impaired bile secretion; receiving warfarin; and who had had a parathyroidectomy were excluded from the study.
Informed consent was obtained from all patients before beginning the study. As a general rule, concomitant 1,25(OH) 2 D 3 preparations and calcium carbonate continued to be administered at the same doses throughout the study period. Calcitonin preparations, ipriflavone preparations, hormone replacement therapy and other drugs that can influence bone metabolism were not co-administered.
Four weeks before the study began, and 3 months, 6 months and 12 months after study initiation, blood was drawn. The blood samples were then analysed for concentrations of vitamin K (K 1 , menatetrenone, MK-7, MK-8; Fig. 2 ), i-PTH, 1,25(OH) 2 D 3 , i-osteocalcin (i-BGP), bone-type alkaline phosphatase (ALP), tartaric acidresistant acidic phosphatase (TRAP), total ALP, calcium and phosphate. The immunoradiometric assay was used to measure i-PTH, the radio-receptor assay used for 1,25(OH) 2 D 3 , enzyme immunoassay method used for bone-type ALP and the p-nitrophenylphosphate substrate method for TRAP. All other analyses were conducted by Mitsubishi Chemical BCL Laboratory.
In addition, the bone mineral content of the entire skeleton (apart from the skull) and lumbar vertebrae (L2 -L4) was determined using dual-energy X-ray absorptiometry (DEXA, Hologic QDR-2000, Waltham, MA, USA) before and 12 months after administration of 
Results
PHARMACODYNAMICS IN SINGLE-DOSE ADMINISTRATION Blood concentrations
The average blood menatetrenone concentration-time profile after administration of a single dose of oral menatetrenone (15 mg) is given in Fig. 3 and Table 3 .
Menatetrenone in CAPD effluents
With the exception of one case (patient 4) in whom menatetrenone-glucuronic acid conjugate was detected in effluents (0.106 ng/ml at 9 h after administration and 0.117 ng/ml at 21.5 h after administration), these substances were not detected.
Pooled urine concentrations
The only notable finding was the presence of K-acid II glucuronic acid conjugate in the 24-h pooled urine samples of two patients (12.9 ng/ml in patient 1 and 15.8 ng/ml in patient 3).
LONG-TERM ADMINISTRATION STUDY Blood menatetrenone concentrations
In all patients, the blood menatetrenone concentration was below the detection limit (0.10 ng/ml) before the study, but above the detection limit in all samples analysed after study initiation, suggesting that oral administration of menatetrenone led to maintenance of pharmacologically effective blood concentrations (Fig. 4) . Regarding vitamin K 1 , MK-7 and MK-8, generally no change was observed after administration, although elevated MK-7 concentrations were observed in some patients.
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Biochemical parameters
After 12 months of menatetrenone administration, 1,25(OH) 2 D 3 and bone-type ALP concentrations fell significantly (P < 0.01 and P < 0.05, respectively; Fig. 5 ). At the same time-point, total ALP rose significantly (P < 0.05).
Bone mineral density
Bone mineral content of the entire skeleton (excluding the skull) and lumbar vertebrae (L2 -L4) obtained before and 12 months after study initiation are shown in Fig. 6 . The bone mineral content changed slightly, but not significantly either in the entire skeleton or lumbar vertebrae.
Discussion
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In a study by Hyodo et al., 6 to those in the healthy adults of this previous study. Menatetrenone and its metabolites were hardly excreted in peritoneal dialysis effluents, and the amount of K-acid II glucuronic acid conjugate detected in 24-h pooled urine was lower in the CAPD patients than in healthy adults. This suggests that menatetrenone blood concentrations equivalent to those in healthy adults may be maintained in CAPD patients, and that administration of an oral menatetrenone preparation at a dose of 45 mg/day may be appropriate.
LONG-TERM ADMINISTRATION STUDY
In the long-term administration study of menatetrenone, no bone metabolism parameters changed considerably, except for significant reductions in bone-type ALP (P < 0.05) and 1,25(OH) 2 D 3 (P < 0.01) 12 months after study initiation. Serum calcium, phosphate and i-PTH parathyroid hormone did not change significantly. The bone formation marker, i-BGP, increased, though not significantly, after 12 months, while the bone resorption marker, TRAP, decreased after 3 months, but returned to baseline at 6 months and thereafter. Because i-BGP and bone-type ALP are expected to exhibit similar changes, it is difficult to interpret the difference observed at 12 months in this study. Of the eight patients studied, five had i-PTH levels less than 100 pg/ml throughout the administration period, and may be said to have a lower rate of bone metabolism. As determined by DEXA, the bone mineral density in the entire skeleton or lumbar vertebrae did not change between before and after 1 year of menatetrenone administration. This finding is in agreement with the absence of considerable biochemical changes in bone metabolism after the study period. Our patients all had lumbar vertebral bone density values of at least 69% relative to those in young adults, and the absence of patients with manifest osteoporosis may account for the lack of improvement in bone mineral content. It was also apparent from this study that an oral menatetrenone preparation could be administered to CAPD patients for an extended period without safety concerns. Hyodo et al. 6 showed that bone mineral density of CAPD patients decreases over a period of 1 year, but this study shows no notable effect on bone metabolism in patients receiving oral menatetrenone at a dose of 45 mg/day. A control study is needed to determine whether this finding suggests that oral menatetrenone has a suppressive effect on bone mineral density reduction.
